Skip to content
PIL Logo

YERVOY 5 mg/ml concentrate for solution for infusion

Last Updated on eMC 17-Nov-2017 View document  | Bristol-Myers Squibb Pharmaceutical Limited Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17-Nov-2017 and displayed until Current

Reasons for adding or updating:

  • Change to section 6 - date of revision
  • Removal of black triangle

Updated on 07-Sep-2017 and displayed until 17-Nov-2017

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 2 - interactions with other medicines, food or drink

Updated on 16-Dec-2016 and displayed until 07-Sep-2017

Reasons for adding or updating:

  • Change to section 6 - date of revision
  • Addition of black triangle

Updated on 03-May-2016 and displayed until 16-Dec-2016

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - what the product contains
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision
  • Change to other sources of information section
  • Removal of black triangle

Updated on 16-Oct-2015 and displayed until 03-May-2016

Reasons for adding or updating:

  • Change to section 4 - how to report a side effect

Updated on 06-Jul-2015 and displayed until 16-Oct-2015

Reasons for adding or updating:

  • Change to section 2 - what you need to know - contraindications
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 06-Oct-2014 and displayed until 06-Jul-2015

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 03-Oct-2014 and displayed until 06-Oct-2014

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 27-Dec-2013 and displayed until 03-Oct-2014

Reasons for adding or updating:

  • Change to section 4 - possible side effects

Updated on 05-Nov-2013 and displayed until 27-Dec-2013

Reasons for adding or updating:

  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 26-Jun-2013 and displayed until 05-Nov-2013

Reasons for adding or updating:

  • Change to section 6 - date of revision

Updated on 18-Jun-2013 and displayed until 26-Jun-2013

Reasons for adding or updating:

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 4 - possible side effects
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 27-Jul-2012 and displayed until 18-Jun-2013

Reasons for adding or updating:

  • Change due to harmonisation of PIL.
  • Updates to formatting
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to information about pregnancy or lactation

Updated on 29-Jul-2011 and displayed until 27-Jul-2012

Reasons for adding or updating:

  • New PIL for new product

Company contact details

Bristol-Myers Squibb Pharmaceutical Limited

Company image
Address

Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH, UK

Medical Information Direct Line

+44 (0) 800 731 1736

Telephone

+44 (0)1895 523 000

Medical Information e-mail

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

ipilimumab

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue